Caspofungin Safety investigation in Gifu Hematology Study Group trial

Caspofungin Safety investigation in Gifu Hematology Study Group trial - GHSG 1401

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017337

Enrollment

Registered

2015-05-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile neutropenia or invasive fungal infection associated with hematological malignancies.

Interventions

An initial dose of 70 mg by intravenous infusion is given followed by 50 mg intravenous daily. Patients who have moderate liver dysfunction consider 35mg intravenous as maintenance dose instead of 50

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are over 18 years, give an informed concent to participate in this study and meet at least one of following criteria. 1) Invasive fungal infection. 2) Persistent febrile neutropenia unresponsive to empric antibiotic therapy.

Exclusion criteria

Exclusion criteria: 1) An allergy of Caspofungin. 2) Severe liver dysfunction. 3) Pregnant or lactating female 4) Prophylaxis for stem cell transplantation patients. 5) Cryptococcosis or mucormycosis. 6) Any other investigator's opinion

Design outcomes

Primary

Measure	Time frame
The efficacy of caspofungin for patients with febrile neutropenia or invasive fungal infection.	—

Countries

Japan

Contacts

Public ContactTakeshi Hara

Gifu University Graduate School of Medicine Department of Hematology

haratake@muh.biglobe.ne.jp058-230-6308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026